SOPHiA GENETICS S.A.(SOPH)Earnings, Financials & Key Ratios
SOPH•NASDAQ
$5.40
$387M mkt cap·Price updated May 7, 2026
AboutSOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.Show more
- Revenue$77M+18.6%
- EBITDA-$61M-5.9%
- Net Income-$79M-26.4%
- EPS (Diluted)-1.17-23.2%
- Gross Margin61.88%-8.2%
- EBITDA Margin-79.46%+10.7%
- Operating Margin-91.79%+10.1%
- Net Margin-102.24%-6.6%
- ROE-110%-118.2%
- ROIC-123.46%-15.1%
- Debt/Equity1.34+329.5%
- Interest Coverage-15.57+49.8%
SOPH Key Insights
SOPHiA GENETICS S.A. (SOPH) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 80 (top 20%)
- ✓Strong 5Y sales CAGR of 22.2%
✗Weaknesses
- ✗Profits declining 15.0% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
SOPH Price & Volume
SOPHiA GENETICS S.A. (SOPH) stock price & volume — 10-year historical chart
Loading chart...
SOPH Growth Metrics
SOPHiA GENETICS S.A. (SOPH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years22.16%
3 Years17.56%
TTM20.85%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-22.31%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-18%
Return on Capital
10 Years-51.99%
5 Years-42.4%
3 Years-47.3%
Last Year-58.75%
SOPH Recent Earnings
SOPHiA GENETICS S.A. (SOPH) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 4/12 qtrs (33%)
Q2 2026Latest
May 5, 2026EPS
$0.27
Est $0.23
-16.1%
Revenue
$22M
Est $20M
+6.3%
Q2 2026
Mar 3, 2026EPS
$0.28
Est $0.24
-17.9%
Revenue
$22M
Est $20M
+5.9%
Q4 2025
Nov 4, 2025EPS
$0.30
Est $0.20
-50.0%
Revenue
$19M
Est $20M
-5.0%
Q3 2025
Aug 5, 2025EPS
$0.33
Est $0.21
+257.1%
Revenue
$18M
Est $18M
-0.2%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.27vs $0.23-16.1% | $22Mvs $20M+6.3% |
| Q2 2026 | Mar 3, 2026 | $0.28vs $0.24-17.9% | $22Mvs $20M+5.9% |
| Q4 2025 | Nov 4, 2025 | $0.30vs $0.20-50.0% | $19Mvs $20M-5.0% |
| Q3 2025 | Aug 5, 2025 | $0.33vs $0.21+257.1% | $18Mvs $18M-0.2% |
Based on last 12 quarters of dataView full earnings history →
SOPH Peer Comparison
SOPHiA GENETICS S.A. (SOPH) competitors in Life Sciences and Precision Medicine Software — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NTRA | 31.16B | 219.82 | -144.62 | 35.9% | -9.03% | -15.28% | 0.13 | |
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 VCYT | 3.25B | 40.76 | 49.71 | 16.01% | 16.25% | 6.86% | 0.03 | |
 CDNA | 1.11B | 21.44 | -53.60 | 13.79% | -1.98% | -2.61% | 0.06 | |
 ILMN | 21.07B | 138.71 | 25.45 | -0.78% | 19.43% | 32.84% | 0.94 | |
 PACB | 498.3M | 1.65 | -0.91 | 3.89% | -341.47% | -11.23% | 141.98 | |
 FLGT | 449.48M | 15.11 | -7.67 | 13.83% | -18.75% | -5.42% | 0.00 | |
 TMO | 176.36B | 474.56 | 26.75 | 3.91% | 15.18% | 13.23% | 0.76 |
Compare SOPH vs Peers
SOPHiA GENETICS S.A. (SOPH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SOPH Income Statement
SOPHiA GENETICS S.A. (SOPH) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 25.36M | 28.4M | 40.45M | 47.56M | 62.37M | 65.17M | 77.27M | 81.18M |
| Revenue Growth % | - | 11.98% | 42.43% | 17.58% | 31.14% | 4.49% | 18.56% | 20.85% |
| Cost of Goods Sold | 7.53M | 10.71M | 15.23M | 16.31M | 19.46M | 21.24M | 29.46M | 26.56M |
| COGS % of Revenue | 29.7% | 37.71% | 37.65% | 34.29% | 31.2% | 32.58% | 38.12% | - |
| Gross Profit | 17.83M▲ 0% | 17.69M▼ 0.8% | 25.22M▲ 42.6% | 31.25M▲ 23.9% | 42.91M▲ 37.3% | 43.94M▲ 2.4% | 47.81M▲ 8.8% | 54.62M▲ 0% |
| Gross Margin % | 70.3% | 62.29% | 62.35% | 65.71% | 68.8% | 67.42% | 61.88% | 67.28% |
| Gross Profit Growth % | - | -0.78% | 42.56% | 23.92% | 37.3% | 2.39% | 8.82% | - |
| Operating Expenses | 50.12M | 55.08M | 96.71M | 119.08M | 117.74M | 110.5M | 118.74M | 126.37M |
| OpEx % of Revenue | 197.61% | 193.94% | 239.09% | 250.37% | 188.77% | 169.56% | 153.67% | - |
| Selling, General & Admin | 35.08M | 36.4M | 70.24M | 84.08M | 81.72M | 76.32M | 85.17M | 91.67M |
| SG&A % of Revenue | 138.33% | 128.16% | 173.65% | 176.79% | 131.03% | 117.11% | 110.23% | - |
| Research & Development | 15.02M | 18.59M | 26.58M | 35.37M | 36.97M | 34.37M | 33.57M | 35.89M |
| R&D % of Revenue | 59.21% | 65.45% | 65.71% | 74.37% | 59.27% | 52.73% | 43.44% | - |
| Other Operating Expenses | 16K | 93K | -108K | -377K | -954K | -183K | 0 | -1000K |
| Operating Income | -32.29M▲ 0% | -37.39M▼ 15.8% | -71.49M▼ 91.2% | -87.82M▼ 22.8% | -74.83M▲ 14.8% | -66.57M▲ 11.0% | -70.92M▼ 6.5% | -71.75M▲ 0% |
| Operating Margin % | -127.3% | -131.64% | -176.73% | -184.66% | -119.97% | -102.14% | -91.79% | -88.39% |
| Operating Income Growth % | - | -15.8% | -91.21% | -22.85% | 14.8% | 11.04% | -6.55% | - |
| EBITDA | -30.37M | -35M | -67.88M | -82.25M | -66.49M | -57.97M | -61.4M | -63.1M |
| EBITDA Margin % | -119.76% | -123.23% | -167.81% | -172.94% | -106.6% | -88.95% | -79.46% | -77.73% |
| EBITDA Growth % | - | -15.22% | -93.96% | -21.17% | 19.16% | 12.81% | -5.91% | -14.69% |
| D&A (Non-Cash Add-back) | 1.91M | 2.39M | 3.61M | 5.57M | 8.34M | 8.6M | 9.53M | 8.65M |
| EBIT | -32.65M | -40.38M | -72.85M | -86.95M | -77.91M | -59.36M | -70.92M | -74.76M |
| Net Interest Income | -890K | -744K | -638K | 685K | 3.96M | 1.45M | -2.68M | -3.85M |
| Interest Income | 86K | 96K | 20K | 1.32M | 4.55M | 3.36M | 1.87M | 1.09M |
| Interest Expense | 976K | 840K | 658K | 639K | 588K | 1.91M | 4.55M | 4.94M |
| Other Income/Expense | -1.34M | -3.84M | -2.02M | 238K | -3.67M | 5.3M | -7.56M | -7.92M |
| Pretax Income | -33.63M▲ 0% | -41.23M▼ 22.6% | -73.51M▼ 78.3% | -87.58M▼ 19.2% | -78.5M▲ 10.4% | -61.27M▲ 21.9% | -78.49M▼ 28.1% | -79.67M▲ 0% |
| Pretax Margin % | -132.6% | -145.16% | -181.72% | -184.16% | -125.85% | -94.01% | -101.57% | -98.14% |
| Income Tax | 162K | -1.89M | 168K | -136K | 486K | 1.22M | 512K | 1.26M |
| Effective Tax Rate % | -0.48% | 4.57% | -0.23% | 0.16% | -0.62% | -2% | -0.65% | -1.58% |
| Net Income | -33.79M▲ 0% | -39.34M▼ 16.4% | -73.67M▼ 87.3% | -87.45M▼ 18.7% | -78.98M▲ 9.7% | -62.49M▲ 20.9% | -79M▼ 26.4% | -80.94M▲ 0% |
| Net Margin % | -133.23% | -138.52% | -182.14% | -183.87% | -126.63% | -95.89% | -102.24% | -99.7% |
| Net Income Growth % | - | -16.42% | -87.28% | -18.7% | 9.68% | 20.88% | -26.41% | -22.31% |
| Net Income (Continuing) | -33.79M | -39.34M | -73.67M | -87.45M | -78.98M | -62.49M | -79M | -80.94M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.53▲ 0% | -0.82▼ 54.7% | -1.33▼ 62.2% | -1.36▼ 2.3% | -1.22▲ 10.3% | -0.95▲ 22.1% | -1.17▼ 23.2% | -1.14▲ 0% |
| EPS Growth % | - | -54.72% | -62.2% | -2.26% | 10.29% | 22.13% | -23.16% | -18% |
| EPS (Basic) | -0.53 | -0.82 | -1.33 | -1.36 | -1.22 | -0.95 | -1.17 | - |
| Diluted Shares Outstanding | 63.86M | 48.02M | 55.3M | 64.1M | 64.75M | 65.78M | 67.54M | 71.14M |
| Basic Shares Outstanding | 63.86M | 48.02M | 55.3M | 64.1M | 64.75M | 65.78M | 67.54M | 71.14M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
SOPH Balance Sheet
SOPHiA GENETICS S.A. (SOPH) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 33.76M | 109.69M | 282.86M | 196.25M | 148.05M | 99.41M | 99.08M | 95.81M |
| Cash & Short-Term Investments | 18.43M | 97.34M | 265.32M | 178.61M | 123.25M | 80.23M | 70.29M | 65.39M |
| Cash Only | 18.07M | 74.63M | 192.96M | 161.31M | 123.25M | 80.23M | 70.29M | 65.39M |
| Short-Term Investments | 366K | 22.72M | 72.36M | 17.31M | 0 | 0 | 0 | 0 |
| Accounts Receivable | 9.71M | 7.85M | 7.09M | 8.05M | 15.21M | 8.69M | 18.53M | 14.31M |
| Days Sales Outstanding | 139.67 | 100.94 | 63.97 | 61.8 | 88.98 | 48.67 | 87.51 | 57.1 |
| Inventory | 3.61M | 3.38M | 5.73M | 5.16M | 6.48M | 5.87M | 6.35M | 7.09M |
| Days Inventory Outstanding | 174.94 | 115.34 | 137.31 | 115.41 | 121.59 | 100.86 | 78.69 | 90.47 |
| Other Current Assets | 339K | 27K | 775K | 731K | 345K | 835K | 758K | 9.02M |
| Total Non-Current Assets | 17.9M | 22.42M | 37.32M | 47.58M | 58.11M | 55.9M | 64.38M | 61.18M |
| Property, Plant & Equipment | 6.45M | 5.54M | 15.96M | 21.4M | 23.1M | 19.38M | 18.05M | 16.8M |
| Fixed Asset Turnover | 3.93x | 5.13x | 2.54x | 2.22x | 2.70x | 3.36x | 4.28x | 4.58x |
| Goodwill | 7.83M | 8.6M | 8.3M | 8.19M | 9M | 8.34M | 9.56M | 35.82M |
| Intangible Assets | 2.4M | 4.68M | 7.38M | 11.78M | 18.19M | 20.66M | 26.34M | 0 |
| Long-Term Investments | 373K | 775K | 0 | 0 | 0 | 0 | 1.98M | 1.98M |
| Other Non-Current Assets | 839K | 711K | 3.7M | 4.28M | 6.1M | 5.76M | 6.21M | 27.27M |
| Total Assets | 51.66M▲ 0% | 132.12M▲ 155.8% | 320.17M▲ 142.3% | 243.84M▼ 23.8% | 206.16M▼ 15.5% | 155.31M▼ 24.7% | 163.46M▲ 5.2% | 157M▲ 0% |
| Asset Turnover | 0.49x | 0.21x | 0.13x | 0.20x | 0.30x | 0.42x | 0.47x | 0.49x |
| Asset Growth % | - | 155.76% | 142.34% | -23.84% | -15.45% | -24.66% | 5.24% | 2.36% |
| Total Current Liabilities | 19.26M | 21.59M | 28.6M | 26.81M | 35.62M | 26.8M | 50.53M | 46.59M |
| Accounts Payable | 1.73M | 1.28M | 2.34M | 2.17M | 2.26M | 1.93M | 5.32M | 12.67M |
| Days Payables Outstanding | 83.79 | 43.66 | 56.01 | 48.57 | 42.32 | 33.21 | 65.86 | 121.67 |
| Short-Term Debt | 2.23M | 2.87M | 0 | 0 | 0 | 0 | 2.7M | 2.71M |
| Deferred Revenue (Current) | 2.1M | 2.64M | 4.07M | 3.43M | 9.49M | 5.73M | 16.72M | 42.31M |
| Other Current Liabilities | 5.73M | 5.25M | 9.16M | 10.27M | 13.58M | 11.22M | 5.32M | 15.27M |
| Current Ratio | 1.75x | 5.08x | 9.89x | 7.32x | 4.16x | 3.71x | 1.96x | 1.96x |
| Quick Ratio | 1.57x | 4.92x | 9.69x | 7.13x | 3.97x | 3.49x | 1.84x | 1.84x |
| Cash Conversion Cycle | 230.82 | 172.62 | 145.26 | 128.64 | 168.25 | 116.32 | 100.35 | 25.9 |
| Total Non-Current Liabilities | 10.14M | 10.02M | 16.17M | 16.9M | 19.09M | 32.02M | 65.78M | 64.71M |
| Long-Term Debt | 1.61M | 457K | 0 | 0 | 0 | 13.24M | 47.73M | 47.84M |
| Capital Lease Obligations | 3.66M | 2.88M | 11.25M | 14.05M | 15.67M | 14.6M | 12.59M | 51.5M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 424K | 424K |
| Other Non-Current Liabilities | 4.79M | 6.54M | 4.92M | 2.85M | 3.42M | 4.18M | 5.04M | 20.23M |
| Total Liabilities | 29.4M | 31.61M | 44.77M | 43.71M | 54.71M | 58.82M | 116.31M | 111.31M |
| Total Debt | 8.46M | 7.25M | 13.06M | 16.74M | 18.6M | 30.03M | 63.02M | 62.42M |
| Net Debt | -9.61M | -67.38M | -179.9M | -144.56M | -104.65M | -50.2M | -7.27M | -2.97M |
| Debt / Equity | 0.38x | 0.07x | 0.05x | 0.08x | 0.12x | 0.31x | 1.34x | 1.34x |
| Debt / EBITDA | - | - | - | - | - | - | - | -0.99x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | 0.05x |
| Interest Coverage | -33.46x | -48.08x | -110.71x | -136.07x | -132.49x | -31.03x | -15.57x | -15.13x |
| Total Equity | 22.25M▲ 0% | 100.51M▲ 351.7% | 275.4M▲ 174.0% | 200.13M▼ 27.3% | 151.44M▼ 24.3% | 96.49M▼ 36.3% | 47.15M▼ 51.1% | 45.69M▲ 0% |
| Equity Growth % | - | 351.67% | 174% | -27.33% | -24.33% | -36.29% | -51.14% | -181.16% |
| Book Value per Share | 0.35 | 2.09 | 4.98 | 3.12 | 2.34 | 1.47 | 0.70 | 0.64 |
| Total Shareholders' Equity | 22.25M | 100.51M | 275.4M | 200.13M | 151.44M | 96.49M | 47.15M | 45.69M |
| Common Stock | 1.95M | 2.46M | 3.33M | 3.46M | 4.05M | 4.19M | 4.81M | 4.81M |
| Retained Earnings | -98.34M | -137.68M | -211.35M | -298.8M | -377.78M | -440.28M | -519.28M | -538.6M |
| Treasury Stock | 0 | 0 | 0 | -117K | -646K | -702K | -1.22M | -1.01M |
| Accumulated OCI | -581K | 8.3M | 12.54M | 23.96M | 53.98M | 61.04M | 89.15M | 92.06M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SOPH Cash Flow Statement
SOPHiA GENETICS S.A. (SOPH) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -31.68M | -31.73M | -57.94M | -70.09M | -48.58M | -42.82M | -38.01M | -38.01M |
| Operating CF Margin % | -124.91% | -111.73% | -143.24% | -147.38% | -77.88% | -65.71% | -49.19% | - |
| Operating CF Growth % | - | -0.16% | -82.6% | -20.98% | 30.7% | 11.84% | 11.23% | -36.47% |
| Net Income | -33.63M | -41.23M | -73.51M | -87.58M | -78.5M | -61.27M | -79M | -80.94M |
| Depreciation & Amortization | 1.91M | 2.39M | 3.61M | 5.57M | 8.34M | 8.6M | 9.53M | 9.98M |
| Stock-Based Compensation | 717K | 1.36M | 8.51M | 13.61M | 15.24M | 16.49M | 0 | 8.5M |
| Deferred Taxes | -447K | -763K | -1.6M | -1.29M | -1.13M | -726K | 0 | -356K |
| Other Non-Cash Items | 1.39M | 2.69M | -1.08M | 873K | 6.6M | -3.33M | 20.75M | 12.65M |
| Working Capital Changes | -1.62M | 3.82M | 6.12M | -1.27M | 872K | -2.58M | 10.71M | 7.28M |
| Change in Receivables | -4.35M | 1.12M | 1.81M | 1.33M | -6.5M | 5.89M | -6.6M | -3.43M |
| Change in Inventory | -862K | 536K | -2.34M | -200K | -874K | 69K | 46K | -1.78M |
| Change in Payables | 5.6M | -185K | 8.98M | -1.43M | 6.87M | -7.38M | 16.93M | 12.45M |
| Cash from Investing | -3.03M | -24.32M | -56.93M | 41.97M | 8.32M | -8.18M | -10.51M | -10.93M |
| Capital Expenditures | -1.35M | -450K | -6.67M | -4.1M | -1.49M | -244K | -8.62M | -5.59M |
| CapEx % of Revenue | 5.34% | 1.58% | 16.49% | 8.61% | 2.4% | 0.37% | 11.16% | - |
| Acquisitions | 0 | 0 | 3.99M | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | -1.68M | -2.75M | -3.99M | -6.28M | -7.73M | -7.93M | 0 | -3.89M |
| Cash from Financing | -1.02M | 107.05M | 237.77M | -1.57M | -2.82M | 11.59M | 34.13M | 46.34M |
| Debt Issued (Net) | -2.78M | -1.67M | -4.08M | -2.32M | -3.04M | 11.18M | 32.69M | -1.41M |
| Equity Issued (Net) | 0 | 107.64M | 231.31M | 0 | 0 | 405K | 1.44M | 16.25M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 1.76M | 1.07M | 10.55M | 748K | 226K | 0 | 0 | 31.5M |
| Net Change in Cash | -35.84M▲ 0% | 56.56M▲ 257.8% | 118.34M▲ 109.2% | -31.66M▼ 126.8% | -38.05M▼ 20.2% | -43.02M▼ 13.1% | -9.94M▲ 76.9% | -3.14M▲ 0% |
| Free Cash Flow | -34.71M▲ 0% | -34.93M▼ 0.6% | -64.61M▼ 84.9% | -80.47M▼ 24.6% | -57.8M▲ 28.2% | -51M▲ 11.8% | -38.59M▲ 24.3% | -45.43M▲ 0% |
| FCF Margin % | -136.87% | -123.01% | -159.73% | -169.21% | -92.67% | -78.25% | -49.93% | -55.96% |
| FCF Growth % | - | -0.64% | -84.95% | -24.55% | 28.17% | 11.77% | 24.34% | 2.59% |
| FCF per Share | -0.54 | -0.73 | -1.17 | -1.26 | -0.89 | -0.78 | -0.57 | -0.57 |
| FCF Conversion (FCF/Net Income) | 0.94x | 0.81x | 0.79x | 0.80x | 0.62x | 0.69x | 0.48x | 0.56x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.56M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SOPH Key Ratios
SOPHiA GENETICS S.A. (SOPH) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -64.09% | -39.2% | -36.78% | -44.93% | -50.41% | -110% | -140.63% |
| Return on Invested Capital (ROIC) | -122.49% | -83.37% | -87.2% | -109.65% | -107.27% | -123.46% | -123.46% |
| Gross Margin | 62.29% | 62.35% | 65.71% | 68.8% | 67.42% | 61.88% | 67.28% |
| Net Margin | -138.52% | -182.14% | -183.87% | -126.63% | -95.89% | -102.24% | -99.7% |
| Debt / Equity | 0.07x | 0.05x | 0.08x | 0.12x | 0.31x | 1.34x | 1.34x |
| Interest Coverage | -48.08x | -110.71x | -136.07x | -132.49x | -31.03x | -15.57x | -15.13x |
| FCF Conversion | 0.81x | 0.79x | 0.80x | 0.62x | 0.69x | 0.48x | 0.56x |
| Revenue Growth | 11.98% | 42.43% | 17.58% | 31.14% | 4.49% | 18.56% | 20.85% |
SOPH Frequently Asked Questions
SOPHiA GENETICS S.A. (SOPH) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
SOPHiA GENETICS S.A. (SOPH) reported $81.2M in revenue for fiscal year 2025. This represents a 220% increase from $25.4M in 2019.
SOPHiA GENETICS S.A. (SOPH) grew revenue by 18.6% over the past year. This is strong growth.
SOPHiA GENETICS S.A. (SOPH) reported a net loss of $80.9M for fiscal year 2025.
Dividend & Returns
SOPHiA GENETICS S.A. (SOPH) has a return on equity (ROE) of -110.0%. Negative ROE indicates the company is unprofitable.
SOPHiA GENETICS S.A. (SOPH) had negative free cash flow of $45.4M in fiscal year 2025, likely due to heavy capital investments.
Explore More SOPH
SOPHiA GENETICS S.A. (SOPH) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates